Table 1 Pharmacological tools to manipulate oncogenic regulatory pathways and lipid mediators associated with cancer metastasis

	Category	Target	Compound	Mechanism	References
		ACC	Soraphen A	ACC inhibitor	Beckers et al. 2007 [11]
		AMPK	Metformin	Activates AMPK, FDA approved	Pollak 2012 [12]
	Regulatory pathways of signaling lipid metabolism	PI3K	GDC-0326	p110α PI3K inhibitor	Soler A et al. 2016 [13]
				PI3K inhibitor
		PI3K/mTOR	NVP-BEZ235		Xie G et al. 2017 [14]
				mTOR inhibitor
		SREBP	Fatostatin	SCAP inhibitor	Kamisuki S et al. 2009 [15]
Signaling lipids	FABPs	FABP4	Carbazole butanoic acid	FABP4 inhibitor	Wang YT et al. 2016 [16]
			Aryl sulfonamide	FABP4 inhibitor	Wang YT et al. 2016 [16]
		FABP5	Pyrazole	FABP5 inhibitor	Wang YT et al. 2016 [16]
	Leukotrienes	Alox5	zileuton	Alox5 inhibitor, LT↓	Wculek SK et al. 2015 [17]
	Leukotrienes	LOX	NDGA	LOX ↓	Koontongkaew et al. 2010 [18]
	Prostaglandin	COX-2	Indomethacin	COX-2↓	Galfi et al. 2005 [19]
		COX-2	Celecoxib	COX-2↓	Wang D et al. 2015 [20]
		PGD2	15-dPGJ 2	Akt ↓, PPARγ ↑	Shin et al. 2009 [21]
			PGJ2 /15-dPGJ2	PPARγ ↑	Chinery et al. 1999 [22]
		PGE2	ONO-AE3-208	EP4 ↓	Yang et al. 2006 [23]
			Curcumin	PGE 2 ↓	Lev-Ari et al. 2005 [24]
			Fish oil	PGE 2 ↓	Mund et al. 2007 [25]
			EPA	PGE 2 ↓	Petrik et al. 2000 [26]
		PGI2	Olive oil	6-keto PGF 1α ↓	Petrik et al. 2000 [26]
	Sphingolipids	SPHK1	FTY720	SPHK1 inhibitor, S1P↓	Patmanathan SN et al. 2016 [27]

ACC, acetyl-CoA carboxylases; Alox5, arachidonate 5-lipoxygenase; AMPK, AMP-activated protein kinase; COX, cyclooxygenase; FABPs, fatty acid-binding proteins; LOX, lipoxygenase; mTOR, mammalian target of rapamycin; PG, prostaglandin; PI3K, phosphoinositide 3-kinase; SREBP, sterol regulatory element-binding proteins; SPHK1, sphingosine kinases

Quick links

Search